Question 1

What are the main differences between the two treatment sequences being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer clinical trial (NCT03635021). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my wild-type RAS status affect my treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer clinical trial (NCT03635021). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from these treatments?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer clinical trial (NCT03635021). Contact the study team or your healthcare provider for specific answers.

Question 4

How long will I need to participate in the trial, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer clinical trial (NCT03635021). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any risks associated with participating in this trial that I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer clinical trial (NCT03635021). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer clinical trial (NCT03635021). Contact the study team or your healthcare provider for specific answers.

What this study is about